Skip to content

Catalyst Pharmaceutical CPRX Intangible Amortization

Intangible Amortization at other companies

Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$2.72M0.0%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$100K-90.0%

Other financials

Income statement

See full
Revenue$149.4M+5.6%
Gross profit$134.9M+9.2%
Operating income$73.2M+15.6%
Net income$63.7M+12.3%
EPS (diluted)$0.50+11.1%

Balance sheet

See full
Cash & equivalents$755.9M+30.2%
Total debt$2.7M-13.3%
Total equity$1.0B+27.5%
Total assets$1.1B+26.3%

Cash flow

See full
Operating cash flow$59.6M-0.8%
CapEx$27.0K
Free cash flow$59.6M-0.8%

Valuation

See full
Market cap$3.84B+2.7%

Profitability

See full
Gross margin86%-0.2pp
Operating margin44.8%+1.6pp
Net margin37.1%+0.2pp
FCF margin34.9%-15.2pp

Returns & leverage

See full
Return on equity24.5%-4.6pp
Debt / equity0.0×
Current ratio7.1×+1.0×

Where this comes from

Reported directly by Catalyst Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Catalyst Pharmaceutical's intangible amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Catalyst Pharmaceutical's intangible amortization?
Catalyst Pharmaceutical (CPRX) reported intangible amortization of $9.7M in Q1 2026.
How has Catalyst Pharmaceutical's intangible amortization changed year-over-year?
Catalyst Pharmaceutical's intangible amortization increased by 3.8% year-over-year, from $9.35M to $9.7M.
What does intangible amortization mean?
Non-cash amortization of intangible assets (patents, customer relationships, technology) acquired through M&A or purchases.